Acadia Pharmaceuticals (ACAD) Free Cash Flow (2010 - 2026)

Acadia Pharmaceuticals' Free Cash Flow history runs 17 years deep, the most recent figure standing at $28.8 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 41.56% year-over-year to $28.8 million; the TTM figure through Mar 2026 stood at $113.6 million (down 23.48% YoY), while the FY2025 annual figure was $105.1 million, down 33.11% from the prior year.
• Free Cash Flow was $28.8 million for Q1 2026 at Acadia Pharmaceuticals, up from -$52.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $85.4 million in Q4 2023 to a low of -$76.3 million in Q1 2022.
• Historically, Free Cash Flow has averaged $11.4 million across 5 years, with a median of $20.3 million in 2025.
• Biggest YoY gain for Free Cash Flow was 457.97% in 2023; the steepest drop was 8009.35% in 2023.
• A 5-year view of Free Cash Flow shows it stood at -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then tumbled by 53.24% to $39.9 million in 2024, then tumbled by 232.08% to -$52.7 million in 2025, then jumped by 154.55% to $28.8 million in 2026.
• The last three Free Cash Flow figures came in at $28.8 million (Q1 2026), -$52.7 million (Q4 2025), and $73.9 million (Q3 2025), per Business Quant data.